Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Dose-Response Study to Assess the Efficacy, Safety, and Pharmacokinetics of XP13512 (GSK1838262) in Patients With Restless Legs Syndrome.

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 01 Oct 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Gabapentin enacarbil (Primary)
Indications Restless legs syndrome
Focus Pharmacokinetics; Registrational
Sponsors GlaxoSmithKline

Most Recent Events

07 Jun 2016 Results of pooled analysis of three trials (NCT00298623, NCT00365352 and NCT01332305)published in the Clinical Therapeutics
19 Apr 2016 Results of pooled post hoc analysis of 3 Phase III trials (NCT00298623, NCT00365352, NCT01332305) published in the CNS Drugs
11 Apr 2016 Results of three phase III studies published in the CNS Drugs.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com